RESEARCH LETTER

CARS2 Hypermethylation Is a Risk Factor for Stage B Heart Failure and Hospitalizations in the Project Baseline Health Study

Jessica A. Regan*[1,2], Jordan Franklin*[2], Kalyani Kottilil[1], Nicholas Cauwenberghs[3], Kenneth W. Mahaffey[4,5,6], Pamela S. Douglas[2,7], Fatima Rodriguez[5,6], Francois Haddad[5,6], Adrian F. Hernandez[2,7], Svati H. Shah[1,2,7], and Lydia Coulter Kwee,[1] for the Project Baseline Health Study Group

[1]Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA

[2]Department of Medicine, Duke University School of Medicine, Durham, NC, USA

[3]Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

[4]Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

[5]Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

[6]Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

[7]Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA

*These authors contributed equally to this work.

Corresponding Author:

Lydia C. Kwee, PhD

300 N. Duke Street, Durham, NC 27701

DUMC Box 104775

Telephone 919-684-0659

Fax 919-684-0943

lydia.kwee@duke.edu

Abstract

The heart is a metabolically active organ with high energy demands that depend on mitochondrial oxidative phosphorylation, however as the heart begins to fail there is metabolic inflexibility and changes in mitochondrial function. Epigenetic changes such as DNA methylation can modify the transcription of genes essential for normal mitochondrial function, however this has not been studied in Stage B or pre-heart failure (HF). In 752 participants from the Project Baseline Health Study, we tested differences in DNA methylation in mitochondrial-related genes for association with Stage B HF compared to Stage A (at-risk for HF). We then validated these findings in 918 participants from the CATHGEN study for risk of incident HF hospitalization. One region on chromosome 13 overlapping with the cysteinyl-tRNA synthetase 2 (*CARS2*) gene, containing five cytosine-phosphate-guanine (CpG) probes, was significantly associated with a small mean regional increase in DNA methylation in Stage B HF (0.63%, Stouffer p=0.005). In CATHGEN, one *CARS2* probe, cg08289839, was significantly associated with time-to-incident HF hospitalization (adjusted HR 1.74 [95% CI 1.18-2.56], FDR p=0.02). In this study of epigenetic changes of mitochondrial genes, these results indicate that *CARS2* DNAm may play a role in HF pathogenesis and should be studied in future HF research.

A 2021 consensus statement defined four stages of heart failure (HF): at-risk for

HF (Stage A), pre-HF (Stage B), HF (Stage C) and advanced HF (Stage D), however,

there is limited understanding of mechanisms by which individuals transition from Stage

A to Stage B and to then symptomatic HF[1]. The heart's high energy demands are

dependent on mitochondrial oxidative phosphorylation of fatty acids for the majority of

ATP generation, while HF is characterized by metabolic inflexibility and increased

reliance on alternative fuel substrates. Epigenetic changes such as DNA methylation

(DNAm) can modify transcription of genes central to mitochondrial function, thereby

impacting downstream cellular and metabolic function. DNAm changes have been

identified in myocardial tissues of subjects with end-stage HF, but whether

mitochondrial-related DNAm may signal early molecular changes in Stage B HF has not

been studied[2]. Here, we investigate the role of DNAm in mitochondrial-related genes in

early-stage HF and in risk of incident HF hospitalization.

The Project Baseline Health Study (PBHS) recruited 2502 participants, of which

752 had either Stage A or Stage B HF along with peripheral blood DNAm profiling from

the Illumina EPIC array[3]. Mean age was 54.4 $\pm$15.8 years, 46.9% of participants were

male and 39.9% self-identified as non-white race. 509 participants were at-risk for HF

(Stage A) defined as history of hypertension, prevalent cardiovascular disease,

diabetes, obesity, chronic kidney disease, prior exposure to cardiotoxins or family

history of cardiomyopathy without structural heart disease. 243 had Stage B HF, defined

as subjects without current or prior signs or symptoms of HF, but with at least one of the

stage A HF characteristics, along with evidence of structural heart disease including left

ventricular mass, hypertrophy, chamber enlargement, valvular heart disease or systolic

or diastolic cardiac dysfunction on echocardiography[4]. We considered 25,774 cytosine-

phosphate-guanine (CpG) probes in 1,192 mitochondrial-related genes identified from

MitoCarta 3.0, Harmonizome 3.0, the PANTHER database and genes previously

described to have DNAm changes or variable expression in HF[2]. Linear regression was

used to test the association of Stage B (vs. stage A) HF with DNAm using the _limma_

package for individual probes and _DMRcate_ for region-based analysis (R v4.4.2).

Models were adjusted for age, self-reported race, sex, body mass index, systolic blood

pressure, creatinine, hypertension, diabetes, coronary disease and cell proportions

derived from a complete blood count. Significance was considered at a false discovery

rate (FDR) $p<0.05$ for both individual probe and region-based analyses. Given that

hypermethylation is a hallmark of cancer, sensitivity analyses were also performed

excluding the 104 participants with a history of cancer. We then tested the association

of significant findings with echocardiographic criteria defining Stage B HF. We validated

significant findings in the CATHGEN cohort. Although CATHGEN does not have stage

B HF phenotyping available, we tested for association between DNAm and time-to-

incident HF hospitalization using Cox proportional hazard models in 918 participants

without prevalent HF, adjusted for the above covariates. Informed consent was obtained

from all participants enrolled in PBHS in accordance with the Helsinki declaration. The

study was approved by a central Institutional Review Board (the WCG IRB; approval

tracking number 20170163, work order number 1-1506365-1) and IRBs at each of the

participating institutions (Stanford University, Duke University, and the California Health

and Longevity Institute).

Baseline characteristics of the participants included in these analyses are shown

in **Table 1**. No individual mitochondrial-related CpGs were associated with Stage B HF

in PBHS after FDR adjustment (**Supplemental Table 1**). In region-based analysis, a

706bp region on chromosome 13 overlapping with the cysteinyl-tRNA synthetase 2

(*CARS2*) gene, which contains five CpGs, was significantly associated with Stage B HF

(Stouffer p=0.005), although the mean regional increase in DNAm was small (0.63%)

(**Supplemental Table 2**). In sensitivity analyses, excluding participants with history of

cancer strengthened the association between the *CARS2* region and Stage B HF

(p=2.1×10^{-7}) (**Supplemental Table 3, Supplemental Table 4**). There were no

significant associations between the five *CARS2* CpG probes and the individual

structural and functional components of Stage B HF (**Supplemental Table 5,**

Supplemental Table 6). In CATHGEN, 254/918 participants had an incident HF

hospitalization event. One of the probes in the *CARS2* region, cg08289839, was

significantly associated with time-to-incident HF hospitalization: adjusted HR 1.74 (95%

CI 1.18-2.56), FDR p=0.02 (**Supplemental Table 7**).

Here, in a study of epigenetic changes of mitochondrial genes, we have shown

that *CARS2* DNAm may play a role in HF pathogenesis, as suggested by its association

with Stage B HF and HF incidence (**Figure 1**). *CARS2* encodes an aminoacyl-tRNA

synthetase that is transcribed by the nuclear genome but exclusively targets

mitochondria, where it is imported and enzymatically catalyzes the ligation of cysteine to

tRNA molecules. *CARS2* is ubiquitously expressed in the heart and many other tissues,

and variants in *CARS2* have been implicated in mitochondrial epileptic encephalopathy,

whereas variants in other aminoacyl-tRNA synthetases and nuclear encoded proteins

impacting mitochondrial translation have been associated with cardiomyopathy[5]. Here

we have used peripheral blood DNAm as a circulating surrogate for myocardial changes

in Stage B HF, as unfortunately, access to myocardial tissue in early HF is likely not

feasible. Further studies should evaluate the role of epigenetic changes in genes

essential to mitochondrial and metabolic function across the spectrum of stages of HF in

large scale human cohorts.

ACKNOWLEDGMENTS

We would like to thank the Project Baseline Health Study and CATHGEN participants

whose data contributed to this work.

Funding

The Project Baseline Health Study and this analysis were funded by Verily Life

Sciences, South San Francisco, California. J.A.R is supported by 1K38HL175026. K.K.

is supported by 1F31HL175914-01.

Ethics Statement

The study was approved by the Duke University and Stanford University Institutional

Review Boards. Informed consent was obtained from all participants enrolled in the

Project Baseline Health Study in accordance with the Declaration of Helsinki.

ClinicalTrials.gov Identifier

NCT03154346, https://clinicaltrials.gov/ct2/show/NCT03154346

Disclosure of Conflicts of Interest

All authors acknowledge institutional research grants from Verily Life Sciences. KM

reports grants from Verily, Afferent, the American Heart Association (AHA), Cardiva

Medical Inc, Gilead, Luitpold, Medtronic, Merck, Eidos, Ferring, Apple Inc, Sanifit, and

St. Jude; grants and personal fees from Amgen, AstraZeneca, Bayer, CSL Behring,

Johnson & Johnson, Novartis, and Sanofi; and personal fees from Anthos, Applied

Therapeutics, Elsevier, Inova, Intermountain Health, Medscape, Mount Sinai, Mundi

Pharma, Myokardia, Novo Nordisk, Otsuka, Portola, SmartMedics, and Theravance

outside the submitted work. FR reports grants from the National Institutes of Health

(NIH) National Heart, Lung, and Blood Institute (R01HL168188; R01HL167974;

R01HL169345), American Heart Association/Harold Amos Medical Faculty

Development program, and Doris Duke Foundation (Grant #2022051); equity from

Carta Healthcare and HealthPals; and consulting fees from HealthPals, Novartis,

NovoNordisk, Esperion Therapeutics, Movano Health, Kento Health, Inclusive Health,

Edwards, Arrowhead Pharmaceuticals, HeartFlow, iRhythm, Amgen, and Cleerly Health

outside the submitted work. AH reports grants and personal fees from AstraZeneca,

Amgen, Bayer, Merck, and Novartis; and personal fees from Boston Scientific outside

the submitted work. The other authors have no conflicts of interest to disclose.

Data Sharing Statement

The deidentified PBHS data corresponding to this study are available upon request for

the purpose of examining its reproducibility. Requests are subject to approval by PBHS

governance.

References

1.   Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of

heart failure: a report of the Heart Failure Society of America, Heart Failure Association

of the European Society of Cardiology, Japanese Heart Failure Society and Writing

Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart

Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New

Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail*. Mar 2021;23(3):352-

380. doi:10.1002/ejhf.2115

2.   Pepin ME, Drakos S, Ha CM, et al. DNA methylation reprograms cardiac

metabolic gene expression in end-stage human heart failure. *Am J Physiol Heart Circ*

Physiol. Oct 1 2019;317(4):H674-H684. doi:10.1152/ajpheart.00016.2019

3.   Arges K, Assimes T, Bajaj V, et al. The Project Baseline Health Study: a step

towards a broader mission to map human health. *NPJ Digit Med*. 2020;3:84.

doi:10.1038/s41746-020-0290-y

4.   Cauwenberghs N, Haddad F, Daubert MA, et al. Clinical and Echocardiographic

Diversity Associated With Physical Fitness in the Project Baseline Health Study:

Implications for Heart Failure Staging. *J Card Fail*. Nov 2023;29(11):1477-1489.

doi:10.1016/j.cardfail.2023.04.008

5.   Coughlin CR, 2nd, Scharer GH, Friederich MW, et al. Mutations in the

mitochondrial cysteinyl-tRNA synthase gene, CARS2, lead to a severe epileptic

encephalopathy and complex movement disorder. *J Med Genet*. Aug 2015;52(8):532-

40. doi:10.1136/jmedgenet-2015-103049

Table 1. Baseline Participant Characteristics

n	752
Age (mean [SD], years)	54.4 (15.8)
Sex, N male (%)	353 (46.9)
Self-reported Race, N (%)	
American Indian or Alaska Native	10 (1.3)
Asian	51 (6.8)
Black or African American	184 (24.5)
Native Hawaiian or Other Pacific Islander	7 (0.9)
Other	48 (6.4)
White	452 (60.1)
Hispanic, N (%)	
Yes	66 (8.8)
No	685 (91.1)
Don't know	1 (0.1)
Systolic Blood Pressure (mean [SD], mmHg)	129.6 (15.5)
Diastolic Blood Pressure (mean [SD], mmHg)	79.4 (10.5)
Body Mass Index (mean [SD], kg/m^2)	31.3 (6.5)
Creatinine (mean [SD], mg/dL)	0.9 (0.3)
Coronary Artery Disease, N (%)	47 (6.2)
Hypertension, N (%)	443 (58.9)
Diabetes, N (%)	171 (22.7)
History of Cancer, N (%)	104 (13.8)
Stage B HF, N (%)	243 (32.3)

Figure 1. *CARS2* **Hypermethylation in Stage B and Incident HF hospitalization.**

Figure 1 Legend: A. Conceptual model exploring the epigenetic changes that may
prompt the transition from Stage A HF characterized by cardiovascular and metabolic
risk factors to Stage B HF. Mitochondrial promoter hypermethylation of *CARS2* which
serves an essential tRNA-synthetase role for mitochondrial protein translation could
lead to subsequent metabolic and mitochondrial dysfunction and ultimately subclinical
cardiac dysfunction and progressive HF. B. Kaplan-Meier curve by tertile of cg08289839
methylation in *CARS2* in CATHGEN cohort for time-to-HF hospitalization. HF, heart
failure; *CARS2*, cysteinyl-tRNA synthetase 2.

256